Innate Pharma develops first-in-class monoclonal antibodies for cancer and inflammatory diseases.

Its drug candidates target regulatory checkpoints of a specific compartment of the immune system: innate immunity. This means receptors – activators or inhibitors – on the surface of innate immunity lymphocytes for potentiating or blocking their activation, as well as the molecules recognized by these receptors on the surface of the tumor cells, in the case of cytotoxic antibodies.